Difference between revisions of "Interferon alfa-2b (Intron-A)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "chemocare.com/chemotherapy/drug-info" to "chemocare.com/druginfo") |
|||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Adult T-cell leukemia-lymphoma]] | *[[Adult T-cell leukemia-lymphoma]] | ||
| − | *[[Chronic | + | *[[Chronic myeloid leukemia]] |
*[[Hairy cell leukemia]] | *[[Hairy cell leukemia]] | ||
*[[Kaposi sarcoma]] | *[[Kaposi sarcoma]] | ||
| Line 23: | Line 23: | ||
==Patient drug information== | ==Patient drug information== | ||
*[https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103132s5190lbl.pdf Interferon alfa-2b (Intron-A) package insert]<ref name="insert"></ref> | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103132s5190lbl.pdf Interferon alfa-2b (Intron-A) package insert]<ref name="insert"></ref> | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/intron-a-interferon-alfa-2b.aspx Interferon alfa-2b (Intron-A) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/intron-a-interferon-alfa-2b.aspx Interferon alfa-2b (Intron-A) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/interferon-alfa-2b-patient-drug-information Interferon alfa-2b (Intron-A) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/interferon-alfa-2b-patient-drug-information Interferon alfa-2b (Intron-A) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/interferon-alfa-2b-patient-drug-information Interferon alfa-2b (Intron-A) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/interferon-alfa-2b-patient-drug-information Interferon alfa-2b (Intron-A) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | * 1986-06-04: Initial FDA approval for treatment of patients 18 years of age or older with [[hairy cell leukemia]]. ''(Based on Golomb et al. 1988)'' |
| − | + | * Uncertain date: Indicated as adjuvant to surgical treatment in patients 18 years of age or older with [[Melanoma|malignant melanoma]] who are free of disease but at high risk for systemic recurrence, within 56 days of surgery. ''(Based on ECOG E1684 & ECOG E1690)'' | |
| − | * Uncertain date: Indicated as adjuvant to surgical treatment in patients 18 years of age or older with [[Melanoma|malignant melanoma]] who are free of disease but at high risk for systemic recurrence, within 56 days of surgery. ''(Based on ECOG E1684)'' | ||
* Uncertain date: Indicated for the initial treatment of clinically aggressive [[Follicular_lymphoma|follicular Non-Hodgkin’s Lymphoma]] in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older. Efficacy of INTRON A therapy in patients with low-grade, low tumor burden follicular Non-Hodgkin’s Lymphoma has not been demonstrated. ''(Based on GELA GELF-86)'' | * Uncertain date: Indicated for the initial treatment of clinically aggressive [[Follicular_lymphoma|follicular Non-Hodgkin’s Lymphoma]] in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older. Efficacy of INTRON A therapy in patients with low-grade, low tumor burden follicular Non-Hodgkin’s Lymphoma has not been demonstrated. ''(Based on GELA GELF-86)'' | ||
* Uncertain date: Indicated for the treatment of selected patients 18 years of age or older with [[Kaposi sarcoma|AIDS-Related Kaposi's Sarcoma]]. ''(Based on Lane et al. 1988 & Volberding et al. 1987)'' | * Uncertain date: Indicated for the treatment of selected patients 18 years of age or older with [[Kaposi sarcoma|AIDS-Related Kaposi's Sarcoma]]. ''(Based on Lane et al. 1988 & Volberding et al. 1987)'' | ||
| Line 68: | Line 67: | ||
|Interferonum Leucocyticum | |Interferonum Leucocyticum | ||
|Intron-A | |Intron-A | ||
| + | |IntronA | ||
|Multiferon | |Multiferon | ||
|Namalvin | |Namalvin | ||
| Line 73: | Line 73: | ||
|Polyferon | |Polyferon | ||
|Realdiron | |Realdiron | ||
| + | |- | ||
|Roceron-A | |Roceron-A | ||
| − | |||
|Sumiferon | |Sumiferon | ||
|- | |- | ||
| Line 88: | Line 88: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | [[Category:Interferon | + | [[Category:Interferon alfas]] |
[[Category:Adult T-cell leukemia-lymphoma medications]] | [[Category:Adult T-cell leukemia-lymphoma medications]] | ||
| − | [[Category:Chronic | + | [[Category:Chronic myeloid leukemia medications]] |
[[Category:Hairy cell leukemia medications]] | [[Category:Hairy cell leukemia medications]] | ||
[[Category:Kaposi sarcoma medications]] | [[Category:Kaposi sarcoma medications]] | ||
Revision as of 23:31, 2 September 2023
General information
Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways. Mechanism not fully understood.[1][2][3]
Route: SC, IM, IV, intralesional
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adult T-cell leukemia-lymphoma
- Chronic myeloid leukemia
- Hairy cell leukemia
- Kaposi sarcoma
- Neuroendocrine tumor
- Pancreatic NET
- Renal cell carcinoma
- Systemic mastocytosis
Diseases for which it was used
Patient drug information
- Interferon alfa-2b (Intron-A) package insert[1]
- Interferon alfa-2b (Intron-A) patient drug information (Chemocare)[4]
- Interferon alfa-2b (Intron-A) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1986-06-04: Initial FDA approval for treatment of patients 18 years of age or older with hairy cell leukemia. (Based on Golomb et al. 1988)
- Uncertain date: Indicated as adjuvant to surgical treatment in patients 18 years of age or older with malignant melanoma who are free of disease but at high risk for systemic recurrence, within 56 days of surgery. (Based on ECOG E1684 & ECOG E1690)
- Uncertain date: Indicated for the initial treatment of clinically aggressive follicular Non-Hodgkin’s Lymphoma in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older. Efficacy of INTRON A therapy in patients with low-grade, low tumor burden follicular Non-Hodgkin’s Lymphoma has not been demonstrated. (Based on GELA GELF-86)
- Uncertain date: Indicated for the treatment of selected patients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. (Based on Lane et al. 1988 & Volberding et al. 1987)
Also known as
Caution, may also contain names for interferon beta, interferon gamma, or interferon alfa-2a.
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Advaferon | Alfaferone | Biogamma | Canferon A | Cytoferon | Egiferon | Feron | Fiblaferon |
| Frone | Finnferon-Alpha | Heberon Alfa R | Humoferon | IFN Alpha | Imufor | Imukin | INF |
| Inferax | Infergen | Inmutag | Interfero | Interferon Alfanative | Interferon Human | Interferon Leucocyticum | Interferon Lymphoblastoid |
| Interferonum Leucocyticum | Intron-A | IntronA | Multiferon | Namalvin | OIF | Polyferon | Realdiron |
| Roceron-A | Sumiferon | ||||||
References
- ↑ 1.0 1.1 1.2 Interferon alfa-2b (Intron-A) package insert
- ↑ Interferon alfa-2b (Intron-A) package insert (locally hosted backup)
- ↑ Intron-A manufacturer's website
- ↑ Interferon alfa-2b (Intron-A) patient drug information (Chemocare)
- ↑ Interferon alfa-2b (Intron-A) patient drug information (UpToDate)
Categories:
- Drugs
- Subcutaneous medications
- Intralesional medications
- Intramuscular medications
- Intravenous medications
- Interferon alfas
- Adult T-cell leukemia-lymphoma medications
- Chronic myeloid leukemia medications
- Hairy cell leukemia medications
- Kaposi sarcoma medications
- Melanoma medications
- Neuroendocrine tumor medications
- Pancreatic NET medications
- Renal cell carcinoma medications
- Systemic mastocytosis medications
- Follicular lymphoma medications (historic)
- Melanoma medications (historic)
- Multiple myeloma medications (historic)
- FDA approved in 1986